StockData
Atossa Therapeutics, Inc. logo

Atossa Therapeutics, Inc. (ATOS) stock

ATOSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.81−0.09 (-4.74%)

Close on Nov 18, 2026Market cap $18.06MP/E –Yield –

Atossa Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Atossa Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$39.25M. For fiscal 2025 it was -$37.14M. The highest annual figure on record is -$3.43M in fiscal 2011.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$37.14M–
FY2024Dec 31, 2024-$27.62M–
FY2023Dec 31, 2023-$31.38M–
FY2022Dec 31, 2022-$27.69M–
FY2021Dec 31, 2021-$20.52M–
FY2020Dec 31, 2020-$14.61M–
FY2019Dec 31, 2019-$17.27M–
FY2018Dec 31, 2018-$11.43M–
FY2017Dec 31, 2017-$7.65M–
FY2016Dec 31, 2016-$7.97M–
FY2015Dec 31, 2015-$12.76M–
FY2014Dec 31, 2014-$12.17M–
FY2013Dec 31, 2013-$10.78M–
FY2012Dec 31, 2012-$5.07M–
FY2011Dec 31, 2011-$3.43M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$8.69M–
Q1 FY2026Mar 31, 2026-$9.87M–
Q4 FY2025Dec 31, 2025-$11.44M–
Q3 FY2025Sep 30, 2025-$9.25M–
Q2 FY2025Jun 30, 2025-$9.04M–
Q1 FY2025Mar 31, 2025-$7.41M–
Q4 FY2024Dec 31, 2024-$7.15M–
Q3 FY2024Sep 30, 2024-$6.39M–
Q2 FY2024Jun 30, 2024-$7.11M–
Q1 FY2024Mar 31, 2024-$6.98M–
Q4 FY2023Dec 31, 2023-$9.02M–
Q3 FY2023Sep 30, 2023-$7.47M–
Q2 FY2023Jun 30, 2023-$7.79M–
Q1 FY2023Mar 31, 2023-$7.10M–
Q4 FY2022Dec 31, 2022-$8.14M–
Q3 FY2022Sep 30, 2022-$8.21M–
Q2 FY2022Jun 30, 2022-$6.60M–
Q1 FY2022Mar 31, 2022-$4.75M–
Q4 FY2021Dec 31, 2021-$4.83M–
Q3 FY2021Sep 30, 2021-$5.16M–
Q2 FY2021Jun 30, 2021-$7.00M–
Q1 FY2021Mar 31, 2021-$3.53M–
Q4 FY2020Dec 31, 2020-$4.23M–
Q3 FY2020Sep 30, 2020-$3.51M–
Q2 FY2020Jun 30, 2020-$3.94M–
Q1 FY2020Mar 31, 2020-$2.94M–
Q4 FY2019Dec 31, 2019-$2.62M–
Q3 FY2019Sep 30, 2019-$3.30M–
Q2 FY2019Jun 30, 2019-$7.29M–
Q1 FY2019Mar 31, 2019-$4.06M–
Q4 FY2018Dec 31, 2018-$2.11M–
Q3 FY2018Sep 30, 2018-$3.31M–
Q2 FY2018Jun 30, 2018-$4.14M–
Q1 FY2018Mar 31, 2018-$1.87M–
Q4 FY2017Dec 31, 2017-$1.99M–
Q3 FY2017Sep 30, 2017-$2.06M–
Q2 FY2017Jun 30, 2017-$1.90M–
Q1 FY2017Mar 31, 2017-$1.70M–
Q4 FY2016Dec 31, 2016-$2.52M–
Q3 FY2016Sep 30, 2016-$1.56M–

More Atossa Therapeutics figures

See a number that looks wrong?